All In Biotech

Drug Trial Radar · NCT04880512

The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

A Double-blinded, Randomized, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

102

Planned (sponsor's estimate)

Start

May 31, 2021

Primary completion

Aug 20, 2022

Study completion Dec 20, 2022

Sponsor

Sponsor type
Industry
First posted
May 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of single ascending doses and multiple ascending doses of SYHX1901 tablets in Chinese healthy subjects

Conditions

  • Healthy Subjects

Interventions

  • SYHX 1901 tabletsDrug

    SYHX 1901, oral tablets, in fasted state

  • PlaceboDrug

    Matching placebo, oral tablets, in fasted state

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of SYHX1901 tabletsTime frame: SAD: up to14 days after the dosing, MAD: up to 7 days after the last dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital of Fudan University

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.